Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 8974 results

  1. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  3. Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]

    In development Reference number: GID-TA11333 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]

    In development Reference number: GID-TA11693 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]

    Awaiting development Reference number: GID-TA11354 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6679]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies [TSID12150]

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Deucravacitinib for treating active psoriatic arthritis [ID6561]

    Awaiting development Reference number: GID-TA11510 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  11. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. MemoKath Stent Insertion

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]

    Awaiting development Reference number: GID-TA11872 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  15. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 10 April 2026.

    Interventional procedures guidance
    In consultation